The following represents disclosure information provided by faculty of the educational and scientific sessions. The Committee have reviewed all presented disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
2022 David A. Karnofsky Memorial Award and Lecture
 
Jedd Wolchok
 
Employment - No Relationships to Disclose
 
Leadership - No Relationships to Disclose
 
Stock and Other Ownership Interests - Apricity Therapeutics; Arsenal IO; Ascentage Pharma; Beigene; Georgiamune; Imvaq Therapeutics; Linnaeus Therapeutics; Maverick Therapeutics; Tizona Therapeutics, Inc.; Trieza Therapeutics
 
Honoraria - No Relationships to Disclose
 
Consulting or Advisory Role - Amgen; Apricity Therapeutics; Ascentage Pharma; AstraZeneca; Bicara Therapeutics; Boehringer Ingelheim; Bristol-Myers Squibb; CellCarta; Daiichi Sankyo,Inc; Dragonfly Therapeutics; Georgiamune; Idera; Imvaq Therapeutics; Larkspur; Maverick Therapeutics; PsiOxus Therapeutics; Recepta Biopharma; Sellas Life Sciences; Surface Oncology; Tizona Therapeutics, Inc.; Trishula Therapeutics; Truvax; Werewolf Therapeutics
 
Speakers' Bureau - No Relationships to Disclose
 
Research Funding - Bristol-Myers Squibb (Inst); Sephora
 
Patents, Royalties, Other Intellectual Property - ALPHAVIRUS REPLICON PARTICLES EXPRESSING TRP2 (Inst); Anti-GITR antibodies and methods of use thereof (Inst); Antigen-binding proteins targeting melanoma differentiation antigens and uses thereof CTLA 4 (Inst); Antigen-binding proteins targeting melanoma differentiation antigens and uses thereof (Inst); CD40 binding Molecules and uses thereof (Inst); CD40 BINDING MOLECULES AND USES THEREOF (Inst); Engineered Vaccinia Viruses for Cancer Immunotherapy
(Inst); I am a co-inventor and receive royalties for a blood test for monitoring myeloid derived suppressor cells. (Inst); I am a co-inventor on a patent for Anti-CD40 agonist mAb fused to Monophosphoryl Lipid A (MPL) for cancer therapy
(Inst); I am a co-inventor on a patent for CAR+ T cells targeting differentiation antigens as means to treat cancer (Inst); I am a co-inventor on a patent for use of oncolytic Newcastle Disease virus. (Inst); I am a co-inventor on an issued patent for DNA vaccines for treatment of cancer in companion animals. (Inst); I am co-inventor and receive royalties for a patent for immune modulating antibodies. (Inst); Immunosuppressive follicular helper-like T cells modulated by immune checkpoint blockade (Inst); Peripheral Blood Phenotype Linked to Outcomes After Immunotherapy Treatment (Inst); Phosphatidylserine Targeting Agents and uses thereof for adoptive T-cell therapies (Inst); RECOMBINANT POXVIRUSES FOR CANCER IMMUNOTHERAPY (Inst); WITH IMMUNOMODULATORY THERAPEUTICS AND METHOD OF MONITORING ABSCOPAL EFFECTS DURING SUCH TREATMENT (Inst)
 
Expert Testimony - No Relationships to Disclose
 
Travel, Accommodations, Expenses - No Relationships to Disclose
 
Other Relationship - No Relationships to Disclose